| Development Programs | Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 | Status |
|---|---|---|---|---|---|---|
| VK2735 Subcutaneous(Dual GLP-1/GIP agonist) | Obesity |
|
Phase 3 planned 2Q25 | |||
| VK2735 Oral (Dual GLP-1/GIP agonist) | Obesity |
|
Phase 2 enrollment completed | |||
| VK2809 (TRβ Agonist) | NASH |
|
Phase 2b VOYAGE trial successfully completed | |||
| VK0214 (TRβ Agonist) | X-ALD |
|
Phase 1b study recently completed | |||
| Product/Target | Indication | Phase |
|---|---|---|
| VK2735 Subcutaneous(Dual GLP-1/GIP agonist) | Obesity | Phase 3 planned 2Q25 |
| VK2735 Oral (Dual GLP-1/GIP agonist) | Obesity | Phase 2 enrollment completed |
| VK2809 (TRβ Agonist) | NASH | Phase 2b VOYAGE trial successfully completed |
| VK0214 (TRβ Agonist) | X_ALD | Phase 1b study recently completed |